Open AccessLabetalol‐Induced Hepatitis in a Patient With Chronic Hepatitis B Infection
Author(s) -
Marinella Mark A.
Publication year - 2002
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1524-6175.2002.00480.x
Subject(s) - medicine , labetalol , asymptomatic , discontinuation , fulminant hepatic failure , gastroenterology , elevated transaminases , hepatitis , fulminant , fulminant hepatitis , chronic hepatitis , immunology , blood pressure , liver transplantation , virus , transplantation
Drug‐induced hepatotoxicity is an important cause of hepatocellular injury. Hepatic necrosis may range from asymptomatic elevations in transaminases to fulminant hepatic failure and death. A 50‐year‐old Asian man developed moderate elevations of hepatic transaminases after commencing labetalol therapy for a hypertensive cerebral hemorrhage. Extensive evaluation revealed evidence of chronic hepatitis B infection, of which the patient was previously not aware. Hepatic transaminases normalized after discontinuation of labetalol.